Get started

China50

$BIDUThe main concern or reason for the tumble in stock price would be China’s increased regulatory scrutiny over tech firms during the past few months. On top of that, people also might be worried about delisting threats for Chinese companies by U.S. regulators. But on the other hand, people should look at how $BIDU is expanding its horizons, for instance, the company ventured into AI space last year, and also launched an autonomous taxi service in China. Yet, the stock price doesn’t seem to reflect optimism or an open mind to Baidu’s evolving business. $BIDU has two strong support levels on the major timeframes. $137 & $80. I suggest keeping your eyes on these levels for an opportunity to go long. Price also oversold on the daily & nearly the weekly. - Factor Four
NASDAQ:BIDULong
by TheBlankFund
4
BTCUSD - WHAT'S NEXT WITH BIDEN WIN CONFIRMED?With a Biden victory declared moments ago, what could be next for BTCUSD? Let's take a look at some Technical indicators: Since March, the correlation between BTC and the USDOLLAR index has had a near perfect negative relationship. For those of you trading stocks as well, it has been a general consensus that Biden will be bad for the Dollar initially and if he wins, there will be a further drawback. I expect this to happen on Monday morning with WallStreet opening much lower in almost every aspect except renewables and China50. This might be the "most organic Bitcoin pump in years" (COINTELEGRAPH). It is steady and the trend direction is clear, unlike the parabolic trend we saw previously. As COINTELEGRAPH points out, such extreme parabolic rallies tend to end off with a "blow-off top / steep correction. Since we are so close to a key resistance and phycological level, $20k is imminent. I and many other analysts don't foresee a drawback when we are so close AND with a Biden win declared. (Currently we are experiencing a healthy drawback/consolidation to $15200, which is normal and good for the continuation of an "organic rally".) Let's take a closer look at what a Biden win might mean for BTC: The good (PURELY FOR BITCOIN, NOT POLITICAL TALK ETC.) - A Stimulus package is imminent, - and probably another lockdown - talks of tax increases - USDOLLAR index will fall further The bad - potential stricter crypto regulation in the future (Biden passed laws as VP that restricted encryption, we will have to see if this links up in future) Conclusion It is common consensus under analysts that a Biden win would be a boost for BTC. As we are already in the middle of a healthy bullrun, $20k is the next stop with minor pullbacks on the way. Please share support by hitting like, many thanks!
BITSTAMP:BTCUSD
by BlockTechEv
11
Bullish Charts - Online Learning in ChinaRYB Education, Inc. provides early childhood education service in the People's Republic of China. The company offers kindergarten services to 2-6-year-old children; and play-and-learn centers services for the joint participation of 0-6-year-old children and their adult family members to promote children's development, foster bonding with family, and prepare them for their entry into kindergartens and primary schools. It also develops and sells educational products and services, such as teaching aids, educational toys, at-home educational products, and school uniforms through franchisees and other business partners, as well as directly to a market of families. As of December 31, 2019, it operated 100 directly operated and 250 franchise kindergartens; and 6 play-and-learn centers. The company was formerly known as Top Margin Limited and changed its name to RYB Education, Inc. in June 2017. RYB Education, Inc. was founded in 1998 and is based in Beijing, China. Daily Chart is Bullish Broke out above the cloud yesterday. Indicators are Bullish Long DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
RLong
by HotCharts
2
Bullish Charts - COVID-19 VaccineGilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California. On 07/11/20, Gilead announced its drug Remdesivir can reduce risk of death in COVID-19 patients. On 07/10/20, Former FDA Commissioner Scott Gottlieb said Remdesivir data showed improved COVID-19 Recovery & Reduced Risk of Death by 62%. The COVID-19 drug alone could be a huge revenue boom for Gilead into the future as many countries stockpile & use it. On the Daily Chart, it looks to me like a Pennant has formed with a breakout coming, Bullish Volume, Bullish PMO, Bullish MACD, Bullish RSI, Bullish OBV, Bullish Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:GILDLong
by HotCharts
1